Factor VII - KM Biologics
Alternative Names: KD2-305Latest Information Update: 13 Feb 2023
At a glance
- Originator KM Biologics
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Factor VII replacements; Thrombin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Haemophilia
Most Recent Events
- 09 Feb 2023 Registered for Haemophilia in Japan (IV) (Meiji Holdings pipeline, February 2023)
- 14 Nov 2022 Preregistration for Haemophilia in Japan (IV) (Meiji Seika Pharma pipeline, November 2022)
- 20 Apr 2022 Meiji Seika anticipates regulatory approval for Haemophilia in Japan in March 2023 (Meiji Holdings pipeline, April 2022)